RxDoctor Payments Data

Charlie Kano, MD

Family Medicine · Merced, CANPI 1003927567

Payments from drug & device makers

$5,222in general payments, 2019–2025

Across 293 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$531
  • GSK$366
  • Pfizer$341
  • Novo Nordisk$338
  • Merck$281
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$257
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,204100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,222 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$268,525
Medicare patients
566
Services billed
10,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin230$238,060
XtandiEnzalutamide14$198,545
OzempicSemaglutide192$191,354
EliquisApixaban202$167,180
FarxigaDapagliflozin Propanediol118$127,383
Trelegy ElliptaFluticasone/Umeclidin/Vilanter154$111,194
TrulicityDulaglutide88$91,305
JanuviaSitagliptin Phosphate76$87,245
XareltoRivaroxaban60$71,103
RybelsusSemaglutide37$55,483
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,144$44,611
MyrbetriqMirabegron59$44,406
Xtampza ErOxycodone Myristate34$42,302
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog117$42,166
OxycontinOxycodone Hcl38$34,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$87$269,385270 claims
Novo NordiskOzempic, Rybelsus$338$246,836229 claims
Astellas Pharma US IncXtandi, Myrbetriq$127$242,95173 claims
PfizerEliquis, Nurtec Odt$341$191,361225 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$366$149,227238 claims
AstraZenecaFarxiga$178$127,383118 claims
MerckJanuvia, Janumet$281$104,61093 claims
Lilly USA, LLCTrulicity$229$91,30588 claims
Johnson & JohnsonXarelto$253$71,10360 claims
Otsuka America Pharmaceutical, Inc.Rexulti$74$28,14420 claims
NovartisEntresto$109$22,52326 claims
AbbVieLinzess$531$14,37423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Merced

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →